Validated RP-HPLC Method for the Assay of Etoricoxib (A Non-Steroidal Anti-Inflammatory Drug) in Pharmaceutical Dosage Forms

A simple, accurate, sensitive and reproducible reverse phase high performance liquid chromatographic method has been developed for the quantitative determination of Etoricoxib in pharmaceutical dosage forms. The assay was performed on Hypersil ODS C-18 (250 x 4.6 mm., 5µm particle size) column using...

Full description

Saved in:
Bibliographic Details
Main Authors: Srinivasu Topalli, T. G. Chandrashekhar, M. Mathrusri Annapurna
Format: Article
Language:English
Published: Wiley 2012-01-01
Series:E-Journal of Chemistry
Online Access:http://dx.doi.org/10.1155/2012/264567
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849307647859228672
author Srinivasu Topalli
T. G. Chandrashekhar
M. Mathrusri Annapurna
author_facet Srinivasu Topalli
T. G. Chandrashekhar
M. Mathrusri Annapurna
author_sort Srinivasu Topalli
collection DOAJ
description A simple, accurate, sensitive and reproducible reverse phase high performance liquid chromatographic method has been developed for the quantitative determination of Etoricoxib in pharmaceutical dosage forms. The assay was performed on Hypersil ODS C-18 (250 x 4.6 mm., 5µm particle size) column using acetonitrile and potassium dihydrogen phosphate buffer (pH 4.2) (46:54 % v/v) as mobile phase with UV detection at 280 nm (flow rate 1.2 ml/min). Bromhexine was used as an internal standard. Quantization was achieved by measurement of the peak area ratio of the drug to the internal standard. The limit of detection (LOD) and the limit of quantification (LOQ) were 0.0704 µg ml-1 and 0.2134 µg ml-1 respectively. Each analysis required no longer than 10 minutes. The calibration curve was linear over the concentration range from 0.5-85.0 µg ml-1. The retention times of Etoricoxib and Bromhexine were found to be 3.083 and 7.631 minutes respectively. The proposed method was validated according to the ICH guidelines and can be used successfully to analyse marketed formulations.
format Article
id doaj-art-1f7722a839f242bfbb3d22465c3d27e2
institution Kabale University
issn 0973-4945
2090-9810
language English
publishDate 2012-01-01
publisher Wiley
record_format Article
series E-Journal of Chemistry
spelling doaj-art-1f7722a839f242bfbb3d22465c3d27e22025-08-20T03:54:42ZengWileyE-Journal of Chemistry0973-49452090-98102012-01-019283283810.1155/2012/264567Validated RP-HPLC Method for the Assay of Etoricoxib (A Non-Steroidal Anti-Inflammatory Drug) in Pharmaceutical Dosage FormsSrinivasu Topalli0T. G. Chandrashekhar1M. Mathrusri Annapurna2Ranbaxy Research Laboratories Ltd., Gurgaon, Haryana, IndiaRanbaxy Research Laboratories Ltd., Gurgaon, Haryana, IndiaDepartment of Pharmaceutical Analysis and Quality Assurance, GITAM Institute of Pharmacy, GITAM University, Visakhaptanam, IndiaA simple, accurate, sensitive and reproducible reverse phase high performance liquid chromatographic method has been developed for the quantitative determination of Etoricoxib in pharmaceutical dosage forms. The assay was performed on Hypersil ODS C-18 (250 x 4.6 mm., 5µm particle size) column using acetonitrile and potassium dihydrogen phosphate buffer (pH 4.2) (46:54 % v/v) as mobile phase with UV detection at 280 nm (flow rate 1.2 ml/min). Bromhexine was used as an internal standard. Quantization was achieved by measurement of the peak area ratio of the drug to the internal standard. The limit of detection (LOD) and the limit of quantification (LOQ) were 0.0704 µg ml-1 and 0.2134 µg ml-1 respectively. Each analysis required no longer than 10 minutes. The calibration curve was linear over the concentration range from 0.5-85.0 µg ml-1. The retention times of Etoricoxib and Bromhexine were found to be 3.083 and 7.631 minutes respectively. The proposed method was validated according to the ICH guidelines and can be used successfully to analyse marketed formulations.http://dx.doi.org/10.1155/2012/264567
spellingShingle Srinivasu Topalli
T. G. Chandrashekhar
M. Mathrusri Annapurna
Validated RP-HPLC Method for the Assay of Etoricoxib (A Non-Steroidal Anti-Inflammatory Drug) in Pharmaceutical Dosage Forms
E-Journal of Chemistry
title Validated RP-HPLC Method for the Assay of Etoricoxib (A Non-Steroidal Anti-Inflammatory Drug) in Pharmaceutical Dosage Forms
title_full Validated RP-HPLC Method for the Assay of Etoricoxib (A Non-Steroidal Anti-Inflammatory Drug) in Pharmaceutical Dosage Forms
title_fullStr Validated RP-HPLC Method for the Assay of Etoricoxib (A Non-Steroidal Anti-Inflammatory Drug) in Pharmaceutical Dosage Forms
title_full_unstemmed Validated RP-HPLC Method for the Assay of Etoricoxib (A Non-Steroidal Anti-Inflammatory Drug) in Pharmaceutical Dosage Forms
title_short Validated RP-HPLC Method for the Assay of Etoricoxib (A Non-Steroidal Anti-Inflammatory Drug) in Pharmaceutical Dosage Forms
title_sort validated rp hplc method for the assay of etoricoxib a non steroidal anti inflammatory drug in pharmaceutical dosage forms
url http://dx.doi.org/10.1155/2012/264567
work_keys_str_mv AT srinivasutopalli validatedrphplcmethodfortheassayofetoricoxibanonsteroidalantiinflammatorydruginpharmaceuticaldosageforms
AT tgchandrashekhar validatedrphplcmethodfortheassayofetoricoxibanonsteroidalantiinflammatorydruginpharmaceuticaldosageforms
AT mmathrusriannapurna validatedrphplcmethodfortheassayofetoricoxibanonsteroidalantiinflammatorydruginpharmaceuticaldosageforms